Methods and compositions for studying, imaging, and treating pain
Saxitoxin analog compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogs, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analog binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject. In embodiments, the present disclosure provides a method for alleviating pain in a subject in need of treatment, the method comprising administering to the subject an effective amount of a saxitoxin analog compound, or a pharmaceutically acceptable salt, isomer, tautomer or prodrug thereof, whereby pain in said subject is alleviated.
1. A compound having structure A shown below, a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt of any of the above:
wherein R1 is —OC(═O)N(R A ) 2 , wherein each occurrence of R A is independently hydrogen, a substituted alkyl group, a branched alkyl group, a cycloalkyl group, or a C 2-12 straight-chain alkyl group, provided that both R A groups are not hydrogen;
wherein R2 is hydrogen;
wherein R3 is hydrogen or alkyl;
wherein R4 is hydrogen or alkyl;
wherein R5 is selected from the group consisting of: hydrogen, oxa, sulfate, —OR A , and —OC(═O)R A , wherein each occurrence of R A can be independently hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, haloalkyl, perhaloalkyl, cycloalkyl, (cycloalkyl)alkyl, substituted phenyl, (substituted phenyl)alkyl, aryl, heteroaryl, heterocyclic, heterocyclo, alkanoyl, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, heteroaryl(alkyl), nitro, oxa, oxo, sulfonyl, sulfonamido, and sulfone;
wherein R6 is selected from the group consisting of: hydrogen, oxa, sulfate, —OR A , and —OC(═O)R A , wherein each occurrence of R A can be independently hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, haloalkyl, perhaloalkyl, cycloalkyl, (cycloalkyl)alkyl, substituted phenyl, (substituted phenyl)alkyl, aryl, heteroaryl, heterocyclic, heterocyclo, alkanoyl, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, heteroaryl(alkyl), nitro, oxa, oxo, sulfonyl, sulfonamido, and sulfone; and
wherein R7 is hydrogen.
2. The compound of claim 1 , wherein R5 and R6 are independently hydrogen or —OSO 3 − .
3. The compound of claim 1 , wherein R5 is —OSO 3 − and R6 is hydrogen.
4. The compound of claim 1 , wherein R5 is hydrogen and R6 is —OSO 3 − .
5. The compound of claim 1 , wherein R5 and R6 are hydrogen.
6. A compound, wherein the compound is any one of the following compounds:
7. The compound of claim 1 , wherein the compound has a longer duration of action of anesthetic effect than saxitoxin.
8. The compound of claim 1 , having structure A shown below, a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt of any of the above:
wherein R1 is —OC(═O)NHR A , and wherein R A is any one of the following: —C 6 H 13 , —C 7 H 15 , i-Pr,
9. A compound having structure A shown below, a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt of any of the above:
wherein R1 is —OC(═O)N(R A ) 2 , wherein each occurrence of R A is independently hydrogen, a substituted alkyl group, a branched alkyl group, a cycloalkyl group, or a C 2-12 straight-chain alkyl group, provided that both R A groups are not hydrogen;
wherein R2 is hydrogen;
wherein R3 is hydrogen or alkyl;
wherein R4 is hydrogen or alkyl;
wherein R5 is selected from the group consisting of: hydrogen, oxa, sulfate, —OR A , and OC(═O)R A , wherein each occurrence of R A can be independently hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, haloalkyl, perhaloalkyl, cycloalkyl, (cycloalkyl)alkyl, substituted phenyl, (substituted phenyl)alkyl, aryl, heteroaryl, heterocyclic, heterocyclo, alkanoyl, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, heteroaryl(alkyl), nitro, oxa, oxo, sulfonyl, sulfonamido, and sulfone;
wherein R6 is selected from the group consisting of: hydrogen, oxa, sulfate, —OR A , and OC(═O)R A , wherein each occurrence of R A can be independently hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, haloalkyl, perhaloalkyl, cycloalkyl, (cycloalkyl)alkyl, substituted phenyl, (substituted phenyl)alkyl, aryl, heteroaryl, heterocyclic, heterocyclo, alkanoyl, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, heteroaryl(alkyl), nitro, oxa, oxo, sulfonyl, sulfonamido, and sulfone; and
wherein R7 is hydrogen; wherein the compound is linked to a label selected from the group consisting of: a radioisotope, a fluorescent moiety, a chemiluminescent moiety, an enzyme, an antibody, an antibody fragment, a magnetic particle, and a quantum dot.
10. A pharmaceutical composition comprising a compound of any one of claims 1 , 2 - 6 , 7 , 8 , and 9 , or a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt of any of the above.